Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

(167) SEXUALLY TRANSMITTED VIRUSES AND THEIR RELATIONSHIP TO FEMALE SEXUAL DISORDERS: A REVIEW
Islam, Nadia, Vegunta, Suneela , Ferguson, D, Islam, N, Galasso, Francesca

The Journal of Sexual Medicine | April 25, 2025 | Volume: 22 | Issue: Supplement_1 | Pages: No page available

10.1093/jsxmed/qdaf068.145 Get It

Abstract Introduction Sexually transmitted viruses (STVs), including Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), Herpes Simplex Virus (HSV), and Hepatitis B Virus (HBV), present major public health challenges due to their high prevelance, chronicity, and transmission rates. Extending beyond immediate health impacts, these viruses affect sexual health and function through mechanisms including chronic inflammation, psychological stress, social stigma, and adverse effects of treatment. While the link between STVs and sexual disorders is acknowledged, it is underexplored in the literature, particularly concerning female sexual health. Current research largely focuses on male sexual dysfunction, especially erectile disorder and its treatment. This review investigates the relationship between STVs and female sexual disorders, examining physiological, psychological, and social factors contributing to sexual health concerns. Enhancing our understanding of this relationship could support clinicians in identifying sexual health concerns in female patients with STVs and providing targeted interventions to optimize sexual health outcomes. Objective This systematic review aims to examine existing literature on the relationship between STVs and female sexual disorders, identifying specific dysfunctions (e.g., pain, desire, arousal, and satisfaction) associated with each virus, underlying mechanisms, and discussing clinical and research implications. Methods A comprehensive literature search was conducted in September 2024 across four databases: Ovid MEDLINE, Ovid EMBASE, Scopus, and Web of Science. A total of 523 references were identified, with 139 duplicates removed, leaving 384 studies for screening based on inclusion and exclusion criteria. Searches combined MeSH (Medical Subject Headings) terms and keywords to capture relevant studies. MeSH terms included “Sexual Dysfunction, Physiological,” “Sexual Dysfunction, Psychological,” “Papillomavirus Infections,” “Herpesvirus 2, Human,” “Hepatitis B,” and “HIV.” Additional keywords included “sexual dysfunction,” “HSV,” “hepatitis,” “HPV,” “woman,” “women,” and “female.” The search was limited to English-language studies. Results A total of 384 studies met the inclusion criteria, with findings revealing associations between specific STVs and various types of female sexual dysfunction. HSV was notably associated with dyspareunia during outbreaks due to genital ulcers, as well as with psychosexual issues linked to concerns about transmissibility and the stigma of visible lesions, negatively affecting intimate relationships. HIV was associated with multifactorial sexual dysfunction, encompassing psychological impacts such as fear of transmission and health-related anxiety, as well as physiological effects like decreased sexual desire from antiretroviral therapy and lipodystrophy. HPV’s relationship with sexual disorders was variable, with some studies connecting it to heightened depression and anxiety following diagnosis, which diminished sexual desire. For HBV, sexual dysfunction correlated with the severity of liver dysfunction, as chronic liver disease in women impairs hormone metabolism and increases sex hormone-binding globulin (SHBG) levels, leading to suppression of the hypothalamic–pituitary-gonadal axis. Conclusions This review highlights a notable relationship between STVs and female sexual dysfunction, emphasizing the need for comprehensive care that addresses both management of the infection and sexual health concerns. Routine screening for sexual health concerns in women with STVs is recommended, along with interdisciplinary approaches to address these complex impacts. Improved recognition and management of sexual disorders in this context can enhance both sexual health outcomes and overall quality of life in affected individuals. Disclosure No.
Cumulative Burden of Digital Health Technologies for Patients With Multimorbidity
Phi, Ngan Thi Thuy , Kunneman, Marleen , Tran, Viet‐Thi , Montori, Víctor M. , Ravaud, Philippe , Tran, Viet-Thi

JAMA Network Open | April 25, 2025 | Volume: 8 | Issue: 4 | Pages: e257288

10.1001/jamanetworkopen.2025.7288 | PMID 40279126 Get It

Importance Digital health technologies (DHTs) aiming to monitor, treat, and manage diseases can be prescribed for patients with multimorbidity; yet most DHTs are designed for individual conditions or problems, while approximately half of patients with chronic conditions have multiple chronic conditions. Objectives To identify DHTs approved by the US Food and Drug Administration (FDA) or listed in the Organisation for the Review of Care and Health Apps (ORCHA) library and prescribable for a hypothetical patient with 5 conditions and to model the number of DHTs this patient should be prescribed to receive benefits health professionals considered important. Evidence Review The FDA databases (Premarket Notification 510(k), Premarket Approval, and De Novo) and the ORCHA App Library from National Health Service Somerset were systematically searched for DHTs registered or updated between January 1, 2019, and December 31, 2022, that could be prescribed to a hypothetical woman with 5 chronic conditions (type 2 diabetes, hypertension, chronic obstructive pulmonary disease, osteoporosis, and osteoarthritis). After abstracting each DHT’s elementary functions (ie, simple and delineated features to monitor, treat, and/or manage conditions), an assessment was undertaken to determine the fewest DHTs this hypothetical patient should be prescribed to receive benefit from digital functions health professionals considered important. Findings A total of 148 DHTs were identified (68 [46%] from FDA databases), of which 96 (65%) involved devices and 52 (35%) were standalone health apps. Only 5 DHTs (3.4%) were intended for 2 or more conditions. DHTs offered 140 elementary functions, ranging from recording, tracking, or visualizing health parameters to providing information to digital therapeutics with just-in-time interventions. The hypothetical patient would need to be prescribed up to 13 apps and 7 devices (a blood pressure monitor, a smartwatch, a pulse oximeter, a connected weight scale, a sensor-attached inhaler to monitor adherence, a lung function monitor, and a blood glucose sensor) to receive benefits from 28 functions at least 3 of 5 health professionals considered important. Conclusions and Relevance This systematic review found that almost all prescribable DHTs were developed for a single condition or problem. Thus, patients with multiple chronic conditions would have to routinize many DHTs concurrently in daily life to benefit from digital functions health professionals considered important.
TIGIT expression dictates the immunosuppressive reprogramming of myeloid cells in glioblastoma
Asad, Mohammad , Inocencio, Julio , Mitrasinovic, Stefan , Aoki, Minori, Crisman, Celina, Lasala, Patrick, Eskandar, Emad N. , Guha, Chandan , Eskandar, Emad N. , Aoki, Minori, Baker, Carly , Hormigo, Adı́lia , Guha, Chandan, Zang, Xingxing , Parney, Ian F. , Himes, Benjamin

No container title available | April 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.04.24.648993 | PMID 40654798 Get It

Abstract Glioblastoma (GBM) is a deadly brain cancer with near-universal recurrence despite maximal treatment for which new innovations are sorely needed. Immunotherapy has yet to make significant gains in GBM treatment despite revolutionizing other cancer therapies, due in part to GBM-mediated immune suppression. This immune derangement proceeds through several mechanisms, but increasing evidence points to critical roles for tumor-derived extracellular vesicles (EVs) and immunosuppressive myeloid cells as key factors in this process. In the present study, we demonstrate broad expression of TIGIT across myeloid cell populations in the GBM microenvironment, a finding recapitulated by conditioning healthy monocytes with GBM-derived EVs. Further, knockdown of TIGIT expression reduced the immunosuppressive polarization of monocytes, resulting in improvement in T cell function. This finding proceeded in an NLRP3-dependent manner, with substantial co-localization of TIGIT and NLRP3 expression prior to knockdown. These findings point to a novel role for TIGIT expression in diverse myeloid cells in the GBM microenvironment as a marker of immunosuppressive activity and further indicate a hierarchy of immunomodulatory protein activity in these myeloid cells, with TIGIT knockdown unmasking the pro-inflammatory activity of NLRP3. This study bolsters understanding of the immunosuppressive complexities of myeloid cells in the GBM microenvironment, while lending further support to prevention or attenuation of immunosuppressive myeloid cell activity as a means of restoring immune function in GBM. Graphical abstract (Created in BioRender. Asad, M. (2025) https://BioRender.com/euiljoq Key Points Tumor-mediated immune suppression is a key barrier to the development of effective immunotherapies for GBM. TIGIT is broadly expressed in myeloid cells within the GBM microenvironment and can be induced by GBM-derived extracellular vesicles. Knockdown of TIGIT reduces immunosuppressive polarization of monocytes and enhances T cell activity via NLRP3 signaling, implicating TIGIT expression as a targetable modifier of immunosuppressive activity in GBM-associated myeloid cells. Importance of the Study Glioblastoma (GBM) remains a formidable clinical challenge, with poor prognosis and limited response to current immunotherapies. This study uncovers a novel immunosuppressive axis involving TIGIT expression in myeloid cells, which are key players in the GBM tumor microenvironment. By demonstrating GBM-derived extracellular vesicles induce TIGIT in healthy monocytes and TIGIT knockdown diminishes immunosuppressive polarization in an NLRP3-dependent manner, this study highlights TIGIT as both a marker and modulator of immune dysfunction in GBM. These findings introduce a functional hierarchy of immunoregulatory proteins in tumor-associated myeloid cells, positioning TIGIT as a potential checkpoint target. Restoring immune activity by disrupting this axis could enhance the efficacy of immunotherapy in GBM. Thus, this research not only advances our understanding of tumor-induced immune suppression but also opens a promising therapeutic avenue to reinvigorate anti-tumor immunity in a cancer type historically resistant to immunotherapeutic approaches.
Activity of contezolid against methicillin-resistant Staphylococcus aureus in a rat model of foreign body osteomyelitis
Herren, Sebastian , Karau, Melissa J. , Koscianski, Christina, Greenwood‐Quaintance, Kerryl E. , Mandrekar, Jayawant N. , Patel, Robin , Herren, Sebastian C , Patel, Robin , Wang, Wen

Microbiology Spectrum | April 25, 2025 | Volume: 13 | Issue: 6 | Pages: No page available

10.1128/spectrum.02372-24 | PMID 40277362 Get It

ABSTRACT Contezolid has activity against methicillin-resistant Staphylococcus aureus (MRSA), a common cause of orthopedic infection. In a rat model of foreign body osteomyelitis, 1.3 log 10 cfu/g bone and 0.5 log 10 cfu/k-wire reduction in MRSA was found in tibiae ( P = 0.0186) and K-wires, respectively, of contezolid-treated compared to untreated rats. No MRSA was recovered from animals receiving rifampin alone or in combination with contezolid or vancomycin. There was no emergence of resistance to contezolid, vancomycin, or rifampin.
Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
Macdonald, Blair , Rosenfeld, Greg , Bruining, David H. , Singh, Siddharth , Jairath, V , Singh, S , McCurdy, Jeffrey D , Macdonald, Blair, Bessissow, Talat , Jairath, Vipul

Alimentary Pharmacology & Therapeutics | April 25, 2025 | Volume: 61 | Issue: 12 | Pages: 1971-1972

10.1111/apt.70153 | PMID 40276820 Get It

Evidence-based guidelines for the pharmacological treatment of migraine, summary version
Ornello, Raffaele , Caponnetto, Valeria , Ahmed, Fayyaz , Al‐Khazali, Haidar M. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia, Cevoli, Sabina , Cheng, Shuli, Chiarugi, Alberto , Christensen, Rune Häckert , Chu, Min Kyung , Crema, Santiago , Stefano, Vincenzo Di , Ekizoğlu, Esme , Fallacara, Adriana , Favoni, Valentina , Garces, Kimberly, Granato, Antonio, Granella, Franco, Ha, Woo‐Seok , Hirata, Koichi , Hoffmann, Jan , Hüssler, Eva-Maria, Hussein, Mona , Jenkins, Bronwyn , Labastida‐Ramírez, Alejandro , Laporta, Anna, Levin, Morris , Lupica, Antonino , Mampreso, Edoardo, Martinelli, Daniele , Orologio, Ilaria, Panneerchelvam, Lavindren Luke, Quattrocchi, Silvia, Romanenko, V.I. , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Sarchielli, Paola , Silvestro, Marcello , Tassorelli, Cristina , Tessitore, Alessandro , Christensen, Rune H. , Ambrosini, Anna , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia , Casillo, Francesco , Cevoli, Sabina , Chiang, Chia-Chun , Chu, Min Kyung , Coppola, Gianluca , Corbelli, Ilenia , De Icco, Roberto , de Tommaso, Marina , Di Stefano, Vincenzo , Diener, Hans-Christoph , Ekizoglu, Esme , Fallacara, Adriana , Favoni, Valentina , Ha, Woo-Seok , Hassan, Amr , Hoffmann, Jan , Hussein, Mona , Iannone, Luigi Francesco , Martinelli, Daniele , Monteith, Teshamae S , Pan, Li-Ling Hope , Rozen, Todd D. , Souza, Marcio Nattan P , Pozo-Rosich, Patricia , Rainero, Innocenzo , Romanenko, Volodymyr , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Schwedt, Todd J , Swerts, Diego Belandrino , Tassorelli, Cristina , Togha, Mansoureh , Vaghi, Gloria , Wang, Shuu-Jiun , Ashina, Messoud , Sacco, Simona , Ornello, Raffaele , Al-Khazali, Haidar M , Ahmed, Fayyaz , Brighina, Filippo , Calabresi, Paolo , Casillo, Francesco , Chiang, Chia‐Chun , Coppola, Gianluca , Lorenzo, Cherubino Di , Diener, Hans‐Christoph , Geppetti, Pierangelo , Goicochea, María Teresa , Guérzoni, Simona , Hassan, Amr , Huessler, Eva‐Maria , Monteith, Teshamae , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Prudenzano, Maria Pia , Quattrocchi, Silvia, Rainero, Innocenzo , Romozzi, Marina , Schwedt, Todd J. , Tessitore, Alessandro , Wang, Shuu‐Jiun , Ashina, Messoud , Sacco, Simona

Cephalalgia | April 25, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1177/03331024251321500 | PMID 40277321 Get It

We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the GRADE approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
Evidence-based guidelines for the pharmacological treatment of migraine
Ornello, Raffaele , Caponnetto, Valeria , Ahmed, Fayyaz , Al‐Khazali, Haidar M. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia, Cevoli, Sabina , Cheng, Shuli, Chiarugi, Alberto , Christensen, Rune Häckert , Chu, Min Kyung , Crema, Santiago , Stefano, Vincenzo Di , Ekizoğlu, Esme , Fallacara, Adriana , Favoni, Valentina , Garces, Kimberly, Granato, Antonio, Granella, Franco, Ha, Woo‐Seok , Hirata, Koichi , Hoffmann, Jan , Hüssler, Eva-Maria, Hussein, Mona , Jenkins, Bronwyn , Labastida‐Ramírez, Alejandro , Laporta, Anna, Levin, Morris , Lupica, Antonino , Mampreso, Edoardo, Martinelli, Daniele , Orologio, Ilaria, Panneerchelvam, Lavindren Luke, Quattrocchi, Silvia, Romanenko, V.I. , Romozzi, Marina , Russo, Antonio , Sances, Grazia , Sarchielli, Paola , Silvestro, Marcello , Tassorelli, Cristina , Tessitore, Alessandro , Christensen, Rune H. , Ashina, Sait , Baraldi, Carlo , Bellotti, Alessia , Casillo, Francesco , Chiang, Chia-Chun , Chu, Min Kyung , Coppola, Gianluca , Corbelli, Ilenia , De Icco, Roberto , de Tommaso, Marina , Di Stefano, Vincenzo , Diener, Hans-Christoph , Favoni, Valentina , Ha, Woo-Seok , Hoffmann, Jan , Hussein, Mona , Iannone, Luigi Francesco , Martinelli, Daniele , Monteith, Teshamae S , Pan, Li-Ling Hope , Rozen, Todd D. , Souza, Marcio Nattan P , Pozo-Rosich, Patricia , Rainero, Innocenzo , Romozzi, Marina , Russo, Antonio , Schwedt, Todd J , Swerts, Diego Belandrino , Tassorelli, Cristina , Togha, Mansoureh , Vaghi, Gloria , Wang, Shuu-Jiun , Ornello, Raffaele , Al-Khazali, Haidar M , Ahmed, Fayyaz , Ambrosini, Anna , Brighina, Filippo , Calabresi, Paolo , Casillo, Francesco , Chiang, Chia‐Chun , Coppola, Gianluca , Lorenzo, Cherubino Di , Diener, Hans‐Christoph , Geppetti, Pierangelo , Goicochea, María Teresa , Guérzoni, Simona , Hassan, Amr , Huessler, Eva‐Maria , Monteith, Teshamae , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Prudenzano, Maria Pia , Quattrocchi, Silvia, Rainero, Innocenzo , Romozzi, Marina , Schwedt, Todd J. , Tessitore, Alessandro , Wang, Shuu‐Jiun , Ashina, Messoud , Sacco, Simona

Cephalalgia | April 25, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1177/03331024241305381 | PMID 40277319 Get It

We here present evidence-based guidelines for the pharmacological treatment of migraine. These guidelines, created by the Italian Society for the Study of Headache and the International Headache Society, aim to offer clear, actionable recommendations to healthcare professionals. They incorporate evidence-based recommendations from randomized controlled trials and expert-based opinions. The guidelines follow the Grading of Recommendations, Assessment, Development and Evaluation approach for assessing the quality of evidence. The guideline development involved a systematic review of literature across multiple databases, adherence to Cochrane review methods, and a structured framework for data extraction and interpretation. Although the guidelines provide a robust foundation for migraine treatment, they also highlight gaps in current research, such as the paucity of head-to-head drug comparisons and the need for long-term outcome studies. These guidelines serve as a resource to standardize migraine treatment and promote high-quality care across different healthcare settings.
Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project
Aggarwal, Anushka , Chandra, Tanya , Keret, Shiri , Pauling, John D , Shamim, Ejaz A. , Miller, Fredrick W., Mammen, Andrew L. , Sambataro, Gianluca , Castañeda, Santos , Dimachkie, Mazen M. , Katsumata, Yasuhiro , Mozaffar, Tahseen , Gunawardena, Harsha , Moghadam‐Kia, Siamak , Ladha, Parth, Mittal, Srijan, Haldule, Saloni , Edpuganti, Namratha , Sridhar, Shreya , Savaliya, Rutvik, Batra, Vanshita, Liewluck, T , Fernandez, Anthony P , Bartoloni, Elena , Shinjo, Samuel Katsuyuki , Katsumata, Yasuhiro , Fujimoto, Manabu , Lilleker, James B , Mozaffar, Tahseen , Rojas Serrano, Jorge , Edpuganti, Namratha , Aggarwal, Rohit , Pauling, John D , Dimachkie, Mazen M , Bonella, Francesco , Liewluck, Teerin , Shinjo, Samuel Katsuyuki , Werth, Victoria P. , Campanilho‐Marques, Raquel , Selva-O’Callaghan, Albert , Mann, H. , Cavagna, Lorenzo , Oddis, Chester V. , Mittal, Srijan, Aggarwal, Rohit

Rheumatology | April 25, 2025 | Volume: 64 | Issue: 9 | Pages: 4930-4936

10.1093/rheumatology/keaf229 | PMID 40286313 Get It

Abstract Objectives The lack of uniform terminology and abbreviations for anti-synthetase syndrome has led to significant challenges in research and clinical practice. This study aimed to establish an international consensus on a standardized nomenclature and abbreviation among a diverse group of global myositis experts and patient representatives. Methods This qualitative project was approved by the International Myositis Assessment and Clinical Studies Group (IMACS). Based on the outcomes of a literature review and preliminary survey, list of terms for nomenclature and abbreviations was finalized. Subsequently, two rounds of the Delphi survey were conducted among myositis experts and patient participants to ascertain current practices and preferences. Using Nominal Group Technique (NGT), the project steering committee developed a consensus nomenclature and abbreviation. Results A total of 241 and 132 myositis experts from six continents, 35 countries and 9 specialities participated in round 1 and round 2 of the Delphi survey, respectively. The results indicated a preference for the terms anti-synthetase syndrome, antisynthetase syndrome and anti-tRNA synthetase syndrome. The abbreviations ASS, ASyS and ASSD were most used, though ASS received notable disapproval. The steering committee, including twenty-five myositis experts and three patient representatives from diverse backgrounds and geographical locations, reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and ASyS as the preferred abbreviation, with 100% and 93.1% votes, respectively. Conclusion The terms anti-synthetase syndrome and ASyS should be adopted as the standard nomenclature and abbreviation in both research and clinical practice. This standardization is expected to increase consistency within the literature.
Abstract LB416: SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi
Riess, Jonathan W. , Marinis, Filippo de , Levy, Benjamin , Bonanno, Laura, Chu, Quincy S. , Novello, Silvia, Baik, Christina S. , Bazhenova, Lyudmila, Cadranel, Jacques , Yang, Tsung‐Ying , Chang, Gee‐Chen , Leventakos, Konstantinos , Livi, Lorenzo, Sequist, Lecia V. , Argue, John R., Xu, Wanning , Ahn, Myung‐Ju , Kim, Tae Min , Bonanno, Laura, Tiseo, Marcello , Sacher, Adrian Gerold , Novello, Silvia , Bazhenova, Lyudmila , Metro, Giulio , Yang, Cheng‐Ta , Livi, Lorenzo, Yang, James Chih‐Hsin , Argue, John, Markovets, Aleksandra A. , Hartmaier, Ryan James

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: LB416-LB416

10.1158/1538-7445.am2025-lb416 Get It

Abstract Background: Savo is an oral, potent and highly selective MET-TKI. In the Phase 2 SAVANNAH study (NCT03778229), savo + osi had a high rate of durable responses in pts with EGFRm advanced NSCLC and high MET OverExp and/or Amp levels. Early clearance of plasma EGFRm may predict outcomes. We report an exploratory analysis of plasma EGFRm clearance and its association with MET tissue biomarker status, ORR and PFS. Methods: Pts with EGFRm advanced NSCLC and MET OverExp and/or Amp with PD on 1L+ osi received savo 300 mg QD, 300 mg BID or 600 mg QD + osi 80 mg QD. MET OverExp/Amp was centrally confirmed (by IHC [Roche], 3+ intensity in ≥50% of tumor cells [MET IHC3+/≥50%]; by FISH [Abbott Molecular], MET gene copy number ≥5 or MET:CEP7 ratio ≥2 [FISH5+], or at higher thresholds of MET IHC3+/≥90% or FISH10+). Baseline (BL) and Wk 3 plasma EGFRm (Ex19del/L858R) were analyzed by ddPCR (Biodesix) as an estimate of tumor burden. MET Amp was not monitored in ctDNA due to low detection sensitivity. Clearance was defined as undetected EGFRm ctDNA at Wk 3, when detected at BL. PFS was investigator-assessed (RECIST 1.1). DCO: Aug 23, 2024. Results: Of 344 pts with evaluable BL ctDNA, 259 (75%) had detected EGFRm ctDNA. Of these, 225 had evaluable ctDNA at Wk 3 (82 [36%] had EGFRm clearance at Wk 3). Confirmed ORR was higher in pts with EGFRm Wk 3 clearance (56/82; 68%) vs non-clearance (38/143; 27%). PFS was longer in pts with vs without EGFRm clearance at Wk 3 (Table). Across all pts evaluable for ctDNA at Wk 3, clearance rates were higher in pts with vs without high MET (69/162 [43%] vs 13/63 [21%]; odds ratio [95% CI] 0.35 [0.16, 0.72]). Similar results were seen in the savo 300 mg QD + osi subgroup. Conclusions: In SAVANNAH, among pts with detected EGFRm ctDNA at BL, clearance at Wk 3 was associated with improved ORR and PFS. Plasma EGFRm clearance at Wk 3 is enriched in pts with MET IHC3+/≥90% or FISH10+ status, consistent with improved efficacy in this biomarker subgroup. Citation Format: Jonathan W. Riess, Filippo de Marinis, Benjamin Levy, Tae Min Kim, Laura Bonanno, Quincy Chu, Marcello Tiseo, Adrian Sacher, Silvia Novello, Christina Baik, Lyudmila Bazhenova, Jacques Cadranel, Giulio Metro, Cheng-Ta Yang, Tsung-Ying Yang, Gee-Chen Chang, Konstantinos Leventakos, Lorenzo Livi, James Chih-Hsin Yang, Lecia V. Sequist, John Argue, Wanning Xu, Aleksandra Markovets, Ryan Hartmaier, Myung-Ju Ahn. SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB416.